European patent for Trajan’s hemaPEN

European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical (Trajan) is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

This follows the recent listings of hemaPEN with the U.S. Food and Drug Administration (US FDA) as Class I for therapeutic and in vitro diagnostic (IVD) use, with the Australian Register of Therapeutic Goods (TGA ARTG) as a Class 1 IVD, and it’s compliance with EU IVD Directive 98/79/EC for supply in the EU and UK as a General IVD.

In today’s environment, where vulnerable communities are practising self-isolation due to COVID-19, remote microsampling facilitates ongoing blood monitoring of chronic disease, and enables continuity-of-care.

hemaPEN provides a convenient sampling procedure for collection and storage of four dried blood spot (DBS) samples. Unlike conventional DBS sampling tools, hemaPEN enables collection of an accurate and precise fixed micro-volume and is designed to maintain sample integrity for quantitative analysis. It is an easy-to-use sophisticated microsampling tool in the hands of non-analysts.

Trajan’s CEO, Mr Stephen Tomisich said, “Having a patent granted for hemaPEN will highlight the unique innovation and technology that is the hemaPEN device. We continue to be motivated by the interest shown in hemaPEN, and how it is being used to transform blood collection and storage.”

Trajan believes in science that benefits people - creating portable and affordable measurement solutions, enabling accurate results to inform preventative healthcare.

Visit to purchase or learn more about hemaPEN, and to sign up for updates.

To learn more about Trajan’s microsampling technologies and capabilities visit

Press release [PDF]

Related news
The third leg in at-home healthcare – microsampling
US FDA listing of Trajan’s hemaPEN® blood microsampling device
CE mark for Trajan’s hemaPEN blood microsampling device, now available for diagnostic use across EU and UK
Trajan’s hemaPEN included on TGA’s ARTG as first blood microsampling device for use in Australia
Pens and prospering as a manufacturer

Featured publication
Deprez, S. et al. “Evaluation of the Performance and Hematocrit Independence of the hemaPEN as a Volumetric Dried Blood Spot Collection Device.” (Analytical Chemistry 2019 91 (22), 14467-14475)

More information

Media contact information
Trajan Scientific and Medical

Interested in hemaPEN and microsampling innovations?

Sign up for hemaPEN updates

Also in News

Trajan Scientific and Medical continues its focus on Microsampling
Trajan Scientific and Medical continues its focus on Microsampling

April 20, 2022

Trajan Scientific and Medical, (Trajan, ASX:TRJ) partnered with researchers at The University of Queensland to develop a skin microbiopsy device which takes tissue samples smaller than 0.5mm in diameter.  It can be used to collect biopsies for skin conditions, including skin cancers.

Read More

Cathy Cordova Appointed Trajan's General Manager of Microsampling Unit
Cathy Cordova Appointed Trajan's General Manager of Microsampling Unit

February 16, 2022

Cathy Cordova has been appointed the General Manager of the consolidated Microsampling Business Unit for Trajan Scientific and Medical.

Read More

Dr Xumei Gao (Bryan) awarded REDI fellowship to partner with Trajan.
Dr Xumei Gao (Bryan) awarded REDI fellowship to partner with Trajan.

January 27, 2022

 Dr Xumei Gao (Bryan) a Postdoctoral Researcher from the ARC Training Centre for Personalized Therapeutics Technologies at the University of Melbourne, has been awarded a REDI fellowship to partner with Trajan.

Read More